Board of Directors

Rick Fair

President and Chief Executive Officer, Director

Rick Fair has a 20-year track record as a strategist and commercial leader in the biopharmaceutical industry. He joined Bellicum as President and CEO in January 2017 from Genentech/Roche where he most recently served as Senior Vice President, Head of Oncology Global Product Strategy, leading oncology product strategy and global commercialization. In this role, he oversaw the global launch of five new molecular entities, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer, and numerous line extensions. He also contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine. Previously, he held several commercial leadership positions within Genentech, including franchise leadership with P&L responsibility for its thrombolytics and oral oncolytics businesses. Prior to Genentech, Mr. Fair spent nine years in the pharmaceutical business at Johnson & Johnson, holding leadership roles in marketing, managed care and reimbursement strategy, and managed care customer management. Mr. Fair received his B.S. from the University of Michigan and his M.B.A. from Columbia Business School.

James Brown


James Brown is Managing Director of AVG Ventures. Prior to joining the investment firm in 2009, Mr. Brown was an independent investor and served on a number of Boards of Directors. He has also held executive operating roles at public and private technology companies, with positions in finance, legal, operations and strategy. From 1999 to 2002, he served as Executive Vice President and General Manager of OpenTV, Inc., a technology and media company, which he helped take through the IPO process. Later, he co-founded and ran the company’s applications business unit, prior to its sale to Liberty Media. Earlier in his career, Mr. Brown was a Partner in the law firms of McDermott, Will & Emery in Menlo Park and Pillsbury Madison & Sutro in San Francisco. He received a B.S. in Accounting from Weber State University and J.D. from BYU Law School where he was Executive Editor of the Law Review.

Jim Daly


Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc. Most recently, Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015, where he was instrumental in commercializing and driving product growth of Jakafi.®  Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a 10-year period, including Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development, and Vice President and General Manager of the Oncology Business Unit. Earlier in his career, he spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit. He earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.

Stephen R. Davis


Stephen Davis has over 20 years of senior management experience in the pharmaceutical industry and currently serves as President and Chief Executive Officer of ACADIA Pharmaceuticals, a biotechnology company focused on developing drug candidates for neurological and central nervous system disorders. Prior to joining ACADIA, Mr. Davis held Executive Vice President and COO roles at Heron Therapeutics and Ardea Biosciences, Inc., where he led core business and finance functions and was instrumental in strategic growth initiatives. Previously, he served successive senior executive positions including CFO, COO, and CEO at Neurogen Corporation, where he completed multiple collaborations and product acquisitions with global pharmaceutical companies. Mr. Davis received his B.S. in Accounting from Southern Nazarene University and completed his J.D. at Vanderbilt University Law School. He recently served on the Boards of Directors at Synageva BioPharma Corporation prior to its acquisition by Alexion Pharmaceuticals and at Furiex Pharmaceuticals prior to its acquisition by Forest (now part of Allergan).

Reid M. Huber, Ph.D.


Reid Huber has over 16 years of experience in pharmaceutical research and clinical development, in both senior leadership and scientific research positions. He currently serves as Executive Vice President and Chief Scientific Officer at Incyte Corporation where he leads drug discovery research primarily in the area of hematology/oncology. Dr. Huber began his career at DuPont Pharmaceuticals in 1998 and was a founding member of the team that started drug discovery at Incyte Corporation in 2002. He received his B.S. in biochemistry/molecular genetics from Murray State University and his Ph.D. in molecular genetics from Washington University, and later trained at the National Institutes of Health.

Frank B. McGuyer


Frank McGuyer is the Founder, Chairman of the Board and CEO of McGuyer Homebuilders Inc. (MHI), one of the largest private builders in Texas, ranked 24th in the Builder 100 ranking of largest homebuilders in the nation in 2012. He is a native Houstonian and earned a B.B.A. with honors at Southern Methodist University (SMU) in Dallas, TX.

Kevin M. Slawin, M.D.


Kevin Slawin founded Bellicum Pharmaceuticals with David Spencer, Ph.D. in 2004. Previously, Dr. Slawin had a long tenure in academic medicine at Baylor College of Medicine, where he was the Dan Duncan Professor in Prostate Cancer and Prostatic Diseases. He was also the Director of the Baylor Prostate Cancer Center until 2007. Dr. Slawin is a pioneer in the field of robotic surgery, co-inventor of P2PSA, the basis of the new FDA approved “prostate health index” prostate cancer screening test, and a thought leader in the diagnosis and treatment of prostate cancer. Dr. Slawin currently serves as director of Vanguard Urologic Institute at Memorial Hermann Medical Group. Memorial Hermann Hospital and Vanguard Urologic Research Foundation, as well as clinical professor of urology at Baylor College of Medicine. He received his B.A. and M.D. at Columbia University, where he was inducted into the Phi Beta Kappa and Alpha Omega Alpha, and completed an American Foundation of Urologic Diseases Scholar Fellowship in Urologic Oncology at Baylor College of Medicine.

Jon P. Stonehouse


Jon P. Stonehouse is currently President and Chief Executive Officer of BioCryst Pharmaceuticals, Inc., and has over 20 years of pharmaceutical executive experience. Prior to joining BioCryst in 2007, he served as Senior Vice President of Corporate Development at Merck KGaA. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company, culminating in the 2007 acquisition of Serono, S.A., the largest biotechnology company in Europe at that time. Mr. Stonehouse received a B.S. in Microbiology from the University of Minnesota-Twin Cities.